Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM10 | O14672 | 20/20 | 1.00 |
| ▸ | MMP2 | P08253 | 19/20 | 1.00 |
| ▸ | MMP9 | P14780 | 14/20 | 1.00 |
| ▸ | MMP3 | P08254 | 9/20 | 1.00 |
| ▸ | ERBB2 | P04626 | 5/20 | 1.00 |
| ▸ | MMP12 | P39900 | 1/20 | 1.00 |
| ▸ | MMP14 | P50281 | 1/20 | 1.00 |
| ▸ | ADAM8 | P78325 | 1/20 | 1.00 |
| ▸ | ADAM17 | P78536 | 1/20 | 1.00 |
| ▸ | ADAM33 | Q9BZ11 | 1/20 | 1.00 |
| ▸ | MMP1 | P03956 | 3/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1366486 | 1.00 | ADAM10 (1.00) | ADAM10MMP2MMP9MMP3ERBB2 | |
| SCHEMBL1365904 | 0.92 | ADAM10 (0.85) | ADAM10MMP2MMP9MMP3ERBB2 | |
| SCHEMBL1366012 | 0.92 | ADAM10 (0.85) | ADAM10MMP2MMP9MMP3ERBB2 | |
| SCHEMBL1365348 | 0.92 | ADAM10 (1.00) | ADAM10MMP2MMP9MMP3ERBB2 | |
| SCHEMBL1364753 | 0.92 | ADAM10 (1.00) | ADAM10MMP2MMP9MMP3ERBB2 | |
| SCHEMBL1363867 | 0.91 | ADAM10 (0.84) | ADAM10MMP2MMP9MMP3ERBB2 | |
| SCHEMBL1366529 | 0.91 | ADAM10 (0.84) | ADAM10MMP2MMP9MMP3ERBB2 | |
| SCHEMBL1366994 | 0.91 | ADAM10 (0.83) | ADAM10MMP2MMP9MMP3ERBB2 | |
| SCHEMBL1366294 | 0.91 | ADAM10 (0.83) | ADAM10MMP2MMP9MMP3ERBB2 | |
| SCHEMBL15428480 | 0.91 | ADAM10 (0.83) | ADAM10MMP2MMP9MMP3ERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11674182-B2 | Biomarker for HER2-positive cancer and anti-HER2 therapy and applications thereof | INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY (KR) | 2023-06-13 | — | — | US | claimed |
| US-20140178399-A1 | ROLE OF ADAM10 AND ITS RELEVANCE TO DISEASE AND THERAPEUTICS | UNIVERSITY OF CHICAGO (US) | 2014-06-26 | — | — | US | claimed |
| US-12461092-B2 | Screening method for APP cleavage activity-controlling substances of ADAMTS4 | SHIMADZU CORPORATION (JP) | 2025-11-04 | — | — | US | disclosed |
| US-12378321-B2 | ADAM17 binding molecules and uses thereof | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2025-08-05 | — | — | US | disclosed |
| US-20230366035-A1 | BIOMARKER FOR HER2-POSITIVE CANCER AND ANTI-HER2 THERAPY AND APPLICATIONS THEREOF | INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY (KR) | 2023-11-16 | — | — | US | disclosed |
| US-20230366035-A1 | BIOMARKER FOR HER2-POSITIVE CANCER AND ANTI-HER2 THERAPY AND APPLICATIONS THEREOF | INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY (KR) | 2023-11-16 | — | — | US | disclosed |
| US-20230366035-A1 | BIOMARKER FOR HER2-POSITIVE CANCER AND ANTI-HER2 THERAPY AND APPLICATIONS THEREOF | INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY (KR) | 2023-11-16 | — | — | US | disclosed |
| US-11674182-B2 | Biomarker for HER2-positive cancer and anti-HER2 therapy and applications thereof | INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY (KR) | 2023-06-13 | — | — | US | disclosed |
| US-11674182-B2 | Biomarker for HER2-positive cancer and anti-HER2 therapy and applications thereof | INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY (KR) | 2023-06-13 | — | — | US | disclosed |
| US-11674182-B2 | Biomarker for HER2-positive cancer and anti-HER2 therapy and applications thereof | INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY (KR) | 2023-06-13 | — | — | US | disclosed |
| US-20230159653-A1 | ADAM17 BINDING MOLECULES AND USES THEREOF | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2023-05-25 | — | — | US | disclosed |
| US-9345677-B2 | Compositions, methods and kits relating to HER-2 cleavage | INCYTE CORPORATION (US) | 2016-05-24 | — | — | US | disclosed |
| US-20140187530-A1 | AZA Spiro Alkane Derivatives as Inhibitors of Metalloproteases | INCYTE CORPORATION (US) | 2014-07-03 | — | — | US | disclosed |
| US-20140178399-A1 | ROLE OF ADAM10 AND ITS RELEVANCE TO DISEASE AND THERAPEUTICS | UNIVERSITY OF CHICAGO (US) | 2014-06-26 | — | — | US | disclosed |
| US-20120263676-A1 | COMPOSITIONS, METHODS AND KITS RELATING TO HER-2 CLEAVAGE | INCYTE CORPORATION, A DELAWARE CORPORATION | 2012-10-18 | — | — | US | disclosed |
| US-8088737-B2 | Treating a cancer, in particular breast cancer, that overexpresses Her-2 by administering an ADAM inhibitor; novel variants of ADAM15 and ADAM15; synergistic effect between inhibition of Her-2 cleavage by an ADAM and certain cytostatic (e.g., Herceptin) and cytotoxic (e.g., Taxol) compounds | INCYTE CORPORATION (US) | 2012-01-03 | — | — | US | disclosed |
| US-20110288068-A1 | AZA SPIRO ALKANE DERIVATIVES AS INHIBITORS OF METALLOPROTEASES | INCYTE CORPORATION | 2011-11-24 | — | — | US | disclosed |
| US-8039471-B2 | Aza spiro alkane derivatives as inhibitors of metalloproteases | INCYTE CORPORATION (US) | 2011-10-18 | — | — | US | disclosed |
| US-7723349-B2 | N-hydroxy-5-methyl-6-{[4-(3-methylphenyl)piperazin-1-yl]carbonyl}-5-azaspiro[2.5]octane-7-carboxamide for example; treating arthritis, cancer, cardiovascular disorders, skin disorders, inflammation and allergic conditions | INCYTE CORPORATION (US) | 2010-05-25 | — | — | US | disclosed |
| US-20040259896-A1 | N-hydroxy-5-methyl-6-{[4-(3-methylphenyl)piperazin-1-yl]carbonyl}-5-azaspiro[2.5]octane-7-carboxamide for example; treating arthritis, cancer, cardiovascular disorders, skin disorders, inflammation and allergic conditions | INCYTE CORPORATION | 2004-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288068-A1 | AZA SPIRO ALKANE DERIVATIVES AS INHIBITORS OF METALLOPROTEASES | MMP9, MMP3, MMP12 | ADAM10 29/4885MMP2 23/4885MMP9 1/4885 |
| US-20140178399-A1 | ROLE OF ADAM10 AND ITS RELEVANCE TO DISEASE AND THERAPEUTICS | ADAM10, ADAM8, ADAM17 | ADAM10 1/4885MMP2 66/4885MMP9 28/4885 |
| US-11674182-B2 | Biomarker for HER2-positive cancer and anti-HER2 therapy and applications thereof | ADAM10, ADAM17, MMP20 | ADAM10 1/4885MMP2 196/4885MMP9 49/4885 |
| US-20140187530-A1 | AZA Spiro Alkane Derivatives as Inhibitors of Metalloproteases | MMP9, MMP3, MMP12 | ADAM10 29/4885MMP2 23/4885MMP9 1/4885 |
| US-20230366035-A1 | BIOMARKER FOR HER2-POSITIVE CANCER AND ANTI-HER2 THERAPY AND APPLICATIONS THEREOF | ADAM10, ADAM17, MMP20 | ADAM10 1/4885MMP2 196/4885MMP9 49/4885 |
| US-20040259896-A1 | N-hydroxy-5-methyl-6-{[4-(3-methylphenyl)piperazin-1-yl]carbonyl}-5-azaspiro[2.5]octane-7-carboxamide for example; treating arthritis, cancer, cardiovascular disorders, skin disorders, inflammation and allergic conditions | MMP9, MMP25, HDAC5 | ADAM10 258/4885MMP2 41/4885MMP9 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.